

# MATRICES-CT

| Co-Primary & Translation |

## RESULTS AND RECOMMENDATIONS OCTOBER 27, 2009

### Industry members of the consortium include:

- AstraZeneca
- Bristol-Myers Squibb
- Eli Lilly
- GlaxoSmithKline
- Johnson & Johnson
- Lundbeck
- Merck
- Pfizer
- Roche
- Sanofi Aventis
- Wyeth

Results from the National Institute of Mental Health (NIMH) MATRICES-CT initiative will be presented on October 27, 2009 at the Hyatt Regency Bethesda Hotel, 7400 Wisconsin Ave, Bethesda, MD. The meeting will provide opportunities for open discussions of each presentation.

MATRICES-CT (co-primary and translation) is an NIMH initiative and an industry-government-academic consortium for facilitating the development of pharmacological agents for cognitive impairments associated with schizophrenia. It was formed to address two obstacles that were identified during the NIMH MATRICES Measurement and Treatment Research to Improve Cognition in Schizophrenia Initiative. MATRICES-CT is a public-private partnership coordinated by the Foundation for NIH.

- The first obstacle is the lack of a consensus regarding functionally-meaningful instruments that can be used in clinical trials of cognition-enhancing drugs. The results from a 4-site study (Validation of Intermediate Measures, VIM) evaluating the validity, psychometric characteristics, and practicality of promising measures will be presented at the meeting. The meeting will also discuss issues in administering these instruments in international clinical trials.
- The second obstacle was the need for versions of MATRICES Consensus Cognitive Battery (MCCB) in languages other than English. MATRICES-CT has supported the translation of the MCCB into six languages that are commonly used for large international trials.

**Individuals who are interested in attending the meeting should register for the meeting by contacting Cat Wendt at [cwendt@mednet.ucla.edu](mailto:cwendt@mednet.ucla.edu) or (310) 268-3731.**

